BioNTech and Gilead Collaborate on Phase 3 Breast Cancer Trial
BioNTech announced a clinical trial collaboration and supply agreement with Gilead to evaluate pumitamig alongside sacituzumab govitecan in triple-negative breast cancer.
Story updates
10:47:12 AM UTC
SquawkNews
BioNTech will adapt its global, double-blind Phase 3 ROSETTA Breast-01 to evaluate pumitamig with Gilead’s sacituzumab govitecan as first-line therapy in PD-L1 low/negative TNBC, pending regulatory approval. Gilead will supply the ADC; BioNTech remains the sponsor.Material DetailsContext by AI Anal…